NCT04289532View on ClinicalTrials.gov

Integrin α6-targeted SPECT Imaging of Breast Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 8, 2018

Primary Completion Date

June 1, 2019

Study Completion Date

June 30, 2019

Conditions
Breast Cancer
Interventions
DRUG

99mTc-RWY

99mTc-RWY were injected into volunteers and patients before the SPECT/CT scans .

Trial Locations (1)

Unknown

Peking University Health Science Center, Beijing

All Listed Sponsors
collaborator

China-Japan Union Hospital, Jilin University

OTHER

collaborator

Sun Yat-sen University

OTHER

lead

Peking University

OTHER

NCT04289532 - Integrin α6-targeted SPECT Imaging of Breast Cancer | Biotech Hunter | Biotech Hunter